MedTrace Logo

T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

NCT06343311 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2025-08-07

No results posted yet for this study

Summary

This is an open-label, dose escalation, multi-center, Phase I/II clinical trial to assess the safety of an autologous T-cell therapy (EB103) and to determine the Recommended Phase II Dose (RP2D) in adult subjects (≥ 18 years of age) who have relapsed/refractory (R/R) B-cell NHL. The study will include a dose escalation phase followed by an expansion phase.

Conditions

  • B-Cell Non-Hodgkin's Lymphoma (NHL)
  • Lymphoma, Non-Hodgkins
  • Lymphomas Non-Hodgkin's B-Cell
  • Non-Hodgkin Lymphoma
  • Non-Hodgkin's Lymphoma
  • Large B-Cell Lymphoma
  • Lymphoma, Non-Hodgkin's, Adult
  • Lymphoma
  • Refractory Non-Hodgkin Lymphoma
  • Relapsed Non-Hodgkin Lymphoma
  • Lymphoma, Non-Hodgkin
  • HIV Associated Lymphoma
  • CNS Lymphoma
  • High-grade B-cell Lymphoma
  • Refractory B-Cell Non-Hodgkin Lymphoma

Interventions

BIOLOGICAL

EB103

EB103 is an autologous T-cell therapy whereby a subject's own T cells are transduced with a lentiviral vector expressing the EB103 transgene.

Sponsors & Collaborators

  • Eureka Therapeutics Inc.

    collaborator INDUSTRY

  • Estrella Biopharma, Inc.

    lead INDUSTRY

Principal Investigators

  • Pei Wang, PhD · Eureka Therapeutics Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-01
Primary Completion
2026-12-31
Completion
2027-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06343311 on ClinicalTrials.gov